Why the study?
Does saralasin acetate infusion improve hemodynamics in a patient with intractable congestive cardiac failure and high-renin hypertension?
Does saralasin acetate infusion improve hemodynamics in a patient with intractable congestive cardiac failure and high-renin hypertension?
Angiotensin II inhibition with saralasin acetate acutely improves hemodynamics in a patient with intractable heart failure and high-renin hypertension.
Answers are grounded in this paper and cite their sources.
May suggest benefit in select high-renin HF; leaves open confirmation in controlled trials before any practice change.
A patient with intractable congestive cardiac failure secondary to renovascular hypertension and severe coronary artery disease was infused with the competitive antagonist of angiotensin II, saralasin acetate. The infusion produced an impressive increase in cardiac output and left ventricular stroke work index in parallel with a striking decrease in the systemic and pulmonary vascular resistance, the coronary resistance, and the myocardial oxygen consumption. It is suggested that angiotensin inhibition may present advantages over other forms of treatment of congestive cardiac failure in selected cases. (JAMA238:880-882, 1977)
No takes yet. Share an insight, caveat, or question.
Haralambos Gavras (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: